Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
Corresponding Author
Naohiro Miyashita
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Correspondence
Naohiro Miyashita, MD, Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Email: [email protected]
Search for more papers by this authorTomoyuki Endo
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorMasahiro Onozawa
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorDaigo Hashimoto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorTakeshi Kondo
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorKatsuya Fujimoto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorKaoru Kahata
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorJunichi Sugita
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorHideki Goto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorToshihiro Matsukawa
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorSatoshi Hashino
Health Care Center, Hokkaido University, Hokkaido, Japan
Search for more papers by this authorTakanori Teshima
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorCorresponding Author
Naohiro Miyashita
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Correspondence
Naohiro Miyashita, MD, Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Email: [email protected]
Search for more papers by this authorTomoyuki Endo
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorMasahiro Onozawa
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorDaigo Hashimoto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorTakeshi Kondo
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorKatsuya Fujimoto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorKaoru Kahata
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorJunichi Sugita
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorHideki Goto
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorToshihiro Matsukawa
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorSatoshi Hashino
Health Care Center, Hokkaido University, Hokkaido, Japan
Search for more papers by this authorTakanori Teshima
Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
Search for more papers by this authorAbstract
Background
Human herpesvirus 6 (HHV-6) encephalitis/myelitis is now a well-known complication after allogeneic stem cell transplantation (allo-HSCT), particularly after cord blood transplantation (CBT). In this study, we evaluated the risk factors of HHV-6 encephalitis/myelitis.
Methods
We evaluated 253 patients who received allo-HSCT from 2007 to 2015 at our institute. HHV-6 encephalitis/myelitis was defined as HHV-6 DNA detection in the cerebrospinal fluid or peripheral blood by polymerase chain reaction in the presence of typical manifestations without other concurrent condition that led to the manifestations.
Results
HHV-6 encephalitis/myelitis occurred in 11 patients (4.5%) (9 encephalitis, 3.7%; 2 myelitis, 0.8%). Multivariate analysis showed that CBT, mycophenolate mofetil (MMF) for graft-versus-host disease prophylaxis, history of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and engraftment syndrome (ES) were significantly associated with incidence of HHV-6 encephalitis/myelitis (P=.025, P=.017, P=.017, and P=.014, respectively).
Conclusion
Although it has been shown that CBT, ES, and history of allo-HSCT are risk factors for HHV-6 encephalitis/myelitis, our study demonstrated MMF is also a risk factor for the disease.
References
- 1Aoki J, Numata A, Yamamoto E, Fujii E, Tanaka M, Kanamori H. Impact of human herpesvirus-6 reactivation on outcomes of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21: 2017-2022.
- 2Ogata M, Satou T, Kadota J, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A multicenter, prospective study. Clin Infect Dis. 2013; 57: 671-681.
- 3Volin L, Lautenschlager I, Juvonen E, Nihtinen A, Anttila VJ, Ruutu T. Human herpesvirus 6 antigenaemia in allogeneic stem cell transplant recipients: Impact on clinical course and association with other beta-herpesviruses. Br J Haematol. 2004; 126: 690-696.
- 4Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: Clinical features and risk factors. J Infect Dis. 2002; 185: 847-853.
- 5Zerr DM, Boeckh M, Delaney C, et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18: 1700-1708.
- 6Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human herpesvirus 6 infection after hematopoietic cell transplantation: Is routine surveillance necessary? Biol Blood Marrow Transplant. 2011; 17: 1562-1568.
- 7de Pagter PJ, Schuurman R, Visscher H, et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: An important risk factor for clinical outcome. Biol Blood Marrow Transplant. 2008; 14: 831-839.
- 8Fujimaki K, Mori T, Kida A, et al. Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol. 2006; 84: 432-437.
- 9Hill JA, Koo S, Guzman Suarez BB, et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: A cohort analysis. Biol Blood Marrow Transplant. 2012; 18: 1638-1648.
- 10Muta T, Fukuda T, Harada M. Human herpesvirus-6 encephalitis in hematopoietic SCT recipients in Japan: A retrospective multicenter study. Bone Marrow Transplant. 2009; 43: 583-585.
- 11Shimazu Y, Kondo T, Ishikawa T, Yamashita K, Takaori-Kondo A. Human herpesvirus-6 encephalitis during hematopoietic stem cell transplantation leads to poor prognosis. Transpl Infect Dis. 2013; 15: 195-201.
- 12Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 39: 705-709.
- 13Yamane A, Mori T, Suzuki S, et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant. 2007; 13: 100-106.
- 14Zerr DM. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol. 2006; 37(Suppl 1): S52-S56.
- 15Zerr DM. Human herpesvirus 6 (HHV-6) disease in the setting of transplantation. Curr Opin Infect Dis. 2012; 25: 438-444.
- 16Mori Y, Miyamoto T, Nagafuji K, et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2010; 16: 1596-1602.
- 17Sakai R, Kanamori H, Motohashi K, et al. Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17: 1389-1394.
- 18Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant. 2009; 15: 1628-1633.
- 19Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15: 367-369.
- 20Sugita J, Kawashima N, Fujisaki T, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant. 2015; 21: 1646-1652.
- 21Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008; 42: 227-240.
- 22Cheng FW, Lee V, Leung WK, et al. HHV-6 encephalitis in pediatric unrelated umbilical cord transplantation: A role for ganciclovir prophylaxis? Pediatr Transplant. 2010; 14: 483-487.
- 23Bhanushali MJ, Kranick SM, Freeman AF, et al. Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology. 2013; 80: 1494-1500.
- 24Hill JA, Boeckh MJ, Sedlak RH, Jerome KR, Zerr DM. Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation. J Clin Virol. 2014; 61: 289-292.
- 25Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: Incidence and clinical significance. J Infect Dis. 2006; 193: 68-79.
- 26Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.
- 27Noda Y, Kodama K, Yasuda T, Takahashi S. Calcineurin-inhibitor-induced pain syndrome after bone marrow transplantation. J Anesth. 2008; 22: 61-63.
- 28Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: What we do and do not know. Bone Marrow Transplant. 2015; 50: 1030-1036.
- 29Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002; 100: 2005-2011.
- 30Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34: 309-317.
- 31Kishi Y, Miyakoshi S, Kami M, et al. Early central nervous system complications after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant. 2004; 10: 561-568.
- 32Yoshihara S, Kato R, Inoue T, et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. Transplantation. 2004; 77: 835-838.
- 33Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47: 85-118.
- 34Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant. 2005; 35: 1089-1093.
- 35Pinana JL, Valcarcel D, Fernandez-Aviles F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant. 2010; 45: 1449-1456.
- 36Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999; 67: 499-504.
- 37Kiehl MG, Schafer-Eckart K, Kroger M, et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc. 2002; 34: 2922-2924.
- 38Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 34: 621-625.
- 39Rorije NM, Shea MM, Satyanarayana G, et al. BK virus disease after allogeneic stem cell transplantation: A cohort analysis. Biol Blood Marrow Transplant. 2014; 20: 564-570.
- 40Hamad N, Shanavas M, Michelis FV, et al. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. Am J Hematol. 2015; 90: 392-399.
- 41Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001; 97: 3380-3389.
- 42Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012; 19: 324-335.
- 43Takatsuka H, Takemoto Y, Yamada S, et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant. 2000; 26: 419-426.
- 44Fujita A, Ihira M, Suzuki R, et al. Elevated serum cytokine levels are associated with human herpesvirus 6 reactivation in hematopoietic stem cell transplantation recipients. J Infect. 2008; 57: 241-248.
- 45Ogata M, Satou T, Kawano R, et al. Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2010; 45: 129-136.
- 46Noguchi T, Yoshiura T, Hiwatashi A, et al. CT and MRI findings of human herpesvirus 6-associated encephalopathy: Comparison with findings of herpes simplex virus encephalitis. Am J Roentgenol. 2010; 194: 754-760.
- 47Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant. 2011; 46: 863-869.
- 48Ogata M, Satou T, Inoue Y, et al. Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: Breakthrough HHV-6 encephalitis following antiviral prophylaxis. Bone Marrow Transplant. 2013; 48: 257-264.
- 49Ogata M, Satou T, Kawano R, et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: A prospective evaluation. Bone Marrow Transplant. 2008; 41: 279-285.
- 50Manichanh C, Grenot P, Gautheret-Dejean A, Debre P, Huraux JM, Agut H. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry. 2000; 40: 135-140.
10.1002/(SICI)1097-0320(20000601)40:2<135::AID-CYTO7>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 51Tanaka-Taya K, Sashihara J, Kurahashi H, et al. Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol. 2004; 73: 465-473.
- 52Hill JA, Sedlak RH, Zerr DM, et al. Prevalence of chromosomally integrated human herpesvirus 6 in patients with human herpesvirus 6-central nervous system dysfunction. Biol Blood Marrow Transplant. 2015; 21: 371-373.
- 53Reddy S, Manna P. Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay. Biol Blood Marrow Transplant. 2005; 11: 530-541.
- 54Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005; 40: 932-940.
